University of Cincinnati

Medical Research Council

Cincinnati Children's Hospital Medical Center

Joseph Floyd Clark

Christopher Joseph Schofield

George Jerome Shaw

Matthew L Flaherty

Thomas Andrew Daniel Cadoux-Hudson

Opeolu Adeoye

Antonius J De Grauw

George Shaw

In one embodiment, a neurological status evaluation apparatus includes a signal generator configured to generate an electromagnetic signal at one or more frequencies, a transmitting antenna coupled to the signal generator and configured to transmit the electromagnetic signal, and a receiving antenna positioned proximate to the transmitting antenna such that an evaluation space is defined between the transmitting antenna and the receiving antenna. The biological tissue under evaluation does not contact the transmitting antenna or the receiving antenna. The receiving antenna receives a modulated electromagnetic signal after propagating through the biological tissue under evaluation. The neurological status evaluation apparatus further includes a spectrum analyzer coupled to the receiving antenna, wherein the spectrum analyzer receives and samples the modulated electromagnetic signal. A computing device is coupled to the spectrum analyzer, calculates an evaluation, and provides a neurological status indicator of the biological tissue under evaluation based on the evaluation parameter.

Apparatuses and methods for neurologic status evaluation using electromagnetic signals

In one embodiment, a neurological status evaluation apparatus includes a signal generator configured to generate an electromagnetic signal at one or more frequencies, a transmitting antenna coupled to the signal generator and configure to transmit the electromagnetic signal, and a receiving antenna positioned proximate to the transmitting antenna such that an evaluation space is defined between the transmitting antenna and the receiving antenna. The biological tissue under evaluation does not contact the transmitting antenna or the receiving antenna. The receiving antenna receives a modulated electromagnetic signal after propagating through the biological tissue under evaluation. The neurological status evaluation apparatus further includes a spectrum analyzer coupled to the receiving antenna, wherein the spectrum analyzer receives and samples the modulated electromagnetic signal. A computing device is coupled to the spectrum analyzer, calculates an evaluation, and provides a neurological status indicator of the biological tissue under evaluation based on the evaluation parameter.

Apparatuses and methods for neurological status evaluation using electromagnetic signals

Methods for treating cognitive dysfunction by modulating brain energy metabolizm using cyclocreatine or a pharmaceutically acceptable salt thereof are discussed.

Methods of treating cognitive dysfunction by modulating brain energy metabolism

A pharmaceutical composition comprising a compound of formula (I) wherein X is an electron withdrawing group, Yis hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, &#x2014;SOR, &#x2014;COR, &#x2014;CONHRor &#x2014;COR, and each of R, Rand R, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl or heterocyclyl, or a compound of formula (II) wherein each of Yand Y, which may be the same or different, is hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, &#x2014;SOR, &#x2014;COR, &#x2014;CONHRor &#x2014;COR, Z is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, &#x2014;CH&#x2550;C(NHR)CH((CH)m COR)(C&#x2550;O)CHor &#x2014;CH(C&#x2550;O)CH((CH)COR)(C&#x2550;O)CH, Ris &#x2014;(CH)COR, each of Rto Rand Rto R, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl or heterocyclyl, and each of m and n, which may be the same or different, is 1 to 6 or a compound of formula (III) wherein each of Yto Y, which may be the same or different, is hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, &#x2014;SOR, &#x2014;COR, &#x2014;CONHRor &#x2014;COR, each of Rand R, which may be the same or different, is &#x2014;(CH)p COR, each of Rto Rand Rto R, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl or heterocyclyl, and p is 1 to 6, or other photolabile degradation product of bilirubin or biliverdin or derivative of a photolabile degradation fragment of bilirubin or biliverdin, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

Degradation fragments

A pharmaceutical composition comprising a compound of formula (I) wherein X is an electron withdrawing group, Yis hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, &#x2014;SOR, &#x2014;COR, &#x2014;CONHRor &#x2014;COR, and each of R, Rand R, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl or heterocyclyl, or a compound of formula (II) wherein each of Yand Y, which may be the same or different, is hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, &#x2014;SOR, &#x2014;COR, &#x2014;CONHRor &#x2014;COR, Z is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, &#x2014;CH&#x2550;C(NHR)CH((CH)COR)(C&#x2550;O)CHor &#x2014;CH(C&#x2550;O)CH((CH)COR)(C&#x2550;O)CH, Ris &#x2014;(CH)COR, each of Rto Rand Rto R, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl or heterocyclyl, and each of m and n, which may be the same or different, is 1 to 6 or a compound of formula (III) wherein each of Yto Y, which may be the same or different, is hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, &#x2014;SOR, &#x2014;COR, &#x2014;CONHRor &#x2014;COR, each of Rand R, which may be the same or different, is &#x2014;(CH)COR, each of RTO Rand Rto R, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl or heterocyclyl, and p is 1 to 6, or other photolabile degradation product of bilirubin or biliverdin or derivative of a photolabile degradation fragment of bilirubin or biliverdin, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent 

Growing community of inventors

Cincinnati, OH, United States of America

Joseph Floyd Clark